@entity12943 and @entity3375 gene expression in laser-capture microdissected and non-microdissected XXXX .

@entity3375 @entity0 @entity5 @entity12943 @entity1558
ADAM (a disintegrin and metalloprotease)12 and @entity3375 are multidomain transmembrane proteins involved in ectodomain shedding of cytokines, growth factors and adhesion molecules, with pivotal activities in the @entity5 microenvironment. The aim of this study was to confirm the up-regulation of @entity3375 and @entity12943 gene splicing variants in @entity0 and to delineate their expression between laser-capture microdissected (LCM) and non-microdissected @entity0 . The gene expression was analyzed by quantitative-reverse transcription-PCR in a total sample of 109 @entity0 paired with corresponding non-neoplastic breast tissues. @entity12943 and 17 proteins expression for corresponding tissue samples was confirmed by immunohistochemistry. ADAM12S, 12L and 17 genes were significantly up-regulated in either malign or benign LCM samples when compared to non- @entity5 controls. For non-LCM samples, it was obtained also an increased expression for @entity12943 and 17 genes in @entity5 , while in @entity5 only @entity12943 variants were significantly up-regulated compared to controls. When benign versus malignant @entity5 were compared, in LCM samples all investigated genes displayed a higher expression in @entity5 , whereas in non-LCM, @entity12943 variants were overexpressed in benign samples. The increased expression of @entity12943 protein in the @entity5 cells and stroma of @entity1558 was immunohistochemically confirmed. These differences between LCM and non-LCM samples were explained by the contribution of the stroma to the expression of this marker. This study underlines the accuracy conferred by homogenous LCM samples on gene expression profiles and confers further evidence regarding the role of @entity12943 and 17 in the breast tumorigenesis and progression.
